Inhibikase Therapeutics, INC

Inhibikase Therapeutics issued a pre-funded warrant to RA Capital Healthcare Fund, L.P. in exchange for 18,030,000 shares of common stock.

Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to its lead candidate, IKT-001, for the treatment of Pulmonary Arterial Hypertension (PAH).

Inhibikase Therapeutics announced the sale of $50 million in common stock through its at-the-market facility to RA Capital Management.

Inhibikase Therapeutics stockholders approved key proposals at the 2026 Annual Meeting, including an increase in equity incentive shares and officer liability limitation.

Inhibikase Therapeutics reported Q1 2026 financial results, highlighting the enrollment of the first patient in its pivotal IMPROVE-PAH Phase 3 study for Pulmonary Arterial Hypertension and progress in securing global regulatory approvals.

Inhibikase Therapeutics has officially commenced patient enrollment for its pivotal Phase 3 IMPROVE-PAH trial evaluating IKT-001 for Pulmonary Arterial Hypertension.

Inhibikase Therapeutics reports increased R&D spending and SG&A costs in Q1 2026, with cash reserves sufficient for at least 12 months.

Inhibikase reported a larger Q3 net loss as it ramps spending ahead of a Phase 2b PAH trial, ending the quarter with $77.3 million in cash and securities and targeting a Q4 2025 study start.

Inhibikase Therapeutics reports increased R&D spend and net loss in Q2 2025, driven by its lead PAH program, while maintaining a strong cash position and securing future funding options.

Inhibikase Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its PAH program and recent corporate developments.

Inhibikase Therapeutics announced its Q3 2024 financial results, highlighting a net loss but also securing a significant $110 million private placement to advance its clinical programs.

Inhibikase Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and ongoing development of its drug candidates.

Inhibikase Therapeutics initiated a global Phase 3 clinical study for its lead product candidate, IKT-001 for Pulmonary Arterial Hypertension, while reporting increased net losses and significant capital raises in 2025.

Inhibikase Therapeutics files an amendment to its annual report to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, and related matters.

Inhibikase Therapeutics shifts strategic focus to its IKT-001 program for Pulmonary Arterial Hypertension (PAH) after pausing development of its Parkinson's disease treatment, supported by recent $110 million private placement.

Inhibikase Therapeutics releases its Code of Business Conduct and Ethics while also providing an update on clinical trials and financial status.

Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Inhibikase Therapeutics, Inc. common stock on July 29, 2026.

Dennis N Berman, a Director of Inhibikase Therapeutics, Inc., reported multiple transactions in common stock on July 30, 2026.

Inhibikase Therapeutics, Inc. reports the grant of stock options to Director Dennis N. Berman.

David Canner, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options on June 26, 2026, as detailed in a recent SEC Form 4 filing.

Arvind Kush, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options.

Roberto Bellini, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options.

Inhibikase Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026.

Inhibikase Therapeutics, Inc. has issued a supplement to its 2025 Annual Meeting proxy statement to clarify disclosures regarding proposed amendments to its 2020 Equity Incentive Plan, including an increased non-employee director award limit and an evergreen provision.

Inhibikase Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Inhibikase Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of its auditor, and approve an amendment to its equity incentive plan.

Inhibikase Therapeutics is holding a special virtual meeting on January 3, 2025, to seek stockholder approval for increasing authorized shares, amending the equity incentive plan, repricing stock options, and altering voting requirements for certain charter amendments.

Inhibikase Therapeutics has filed a definitive proxy statement with the SEC.

Inhibikase Therapeutics has filed a registration statement for the resale of up to 4,761,904 shares of common stock by a selling stockholder upon the exercise of outstanding warrants.

Inhibikase Therapeutics files an amendment to its S-1 registration statement to update the legal opinion regarding its proposed public offering of common stock and warrants.

Inhibikase Therapeutics plans a best-efforts public offering of common stock and warrants to raise capital for general corporate purposes.

Inhibikase Therapeutics launches a best-efforts offering of common stock and warrants to fund clinical trials and biomarker programs for Parkinson's disease and Multiple System Atrophy.

Inhibikase Therapeutics plans a best-efforts public offering of common stock and warrants to fund clinical trials and corporate purposes.

Inhibikase Therapeutics is planning a best-efforts public offering of common stock and accompanying warrants, along with pre-funded warrants for certain investors.

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 9.9% of Inhibikase Therapeutics' common stock.

RA Capital Management and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of 15.9% of Inhibikase Therapeutics' common stock.

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Trails Edge Capital Partners and Ortav Yehudai have reported a 6.1% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 5.68% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates report a 10.8% beneficial ownership stake in Inhibikase Therapeutics, Inc.